TherapeuticsMD Announces Participation in 2016 BioFlorida Conference

– Company supports BioFlorida and statewide life sciences industry
growth –

BOCA RATON, Fla.–(BUSINESS WIRE)–TherapeuticsMD, Inc. (NYSE MKT: TXMD), an innovative women’s healthcare
company headquartered in Boca Raton, announced the company’s
participation in the 2016 BioFlorida Conference to be held in
Jacksonville from December 11-13. Two TherapeuticsMD company executives,
Chief Executive Officer Robert Finizio and Chief Product Officer Julia
Amadio, will serve as industry expert guest speakers at the conference
on the featured topics of Innovation and Women’s Health, respectively.

“The BioFlorida conference is an important opportunity to bring together
members of the local life sciences industry, share best practices and
learn from our respective experiences,” said TherapeuticsMD CEO Robert
G. Finizio. “TherapeuticsMD is a strong supporter of the regional life
sciences presence in South Florida as we pursue our mission to bring
innovative healthcare solutions to women at all stages of their lives.”

TherapeuticsMD is a biopharmaceutical company currently developing a
pipeline of hormone therapy products for post-menopausal women and
marketing a suite of prescription prenatal vitamins throughout the
United States. The company has over 175 employees, approximately 100 of
whom work in the company’s Boca Raton office.

TherapeuticsMD is a sponsor of the 2016 BioFlorida Conference and an
active member of BioFlorida, the statewide association representing the
life sciences industry.

About BioFlorida

BioFlorida is the voice of Florida’s life sciences
industry, representing nearly 6,000 establishments and
research organizations in the biotechnology, pharmaceuticals, medical
technology and bioagriculture sectors that collectively employ nearly
83,000 Floridians. The annual conference is BioFlorida’s largest and
most comprehensive event of the year featuring an informative program
showcasing science, business and public policy issues. More information
is available on BioFlorida’s website:

About TherapeuticsMD, Inc.

TherapeuticsMD, Inc. is an innovative healthcare company focused on
developing and commercializing products exclusively for women. With its
SYMBODA™ technology, TherapeuticsMD is developing hormone therapy
pharmaceutical products to enable delivery of bio-identical hormones
through a variety of dosage forms and administration routes. The
company’s clinical development pipeline includes two phase 3 products.
The company also manufactures and distributes branded and generic
prescription prenatal vitamins as well as over-the-counter vitamins
under the vitaMedMD® and BocaGreenMD® brands. More
information is available at the following websites:,

Forward-Looking Statements

This press release by TherapeuticsMD, Inc. may contain
forward-looking statements. Forward-looking statements may include, but
are not limited to, statements relating to TherapeuticsMD’s objectives,
plans and strategies as well as statements, other than historical facts,
that address activities, events or developments that the company
intends, expects, projects, believes or anticipates will or may occur in
the future. These statements are often characterized by terminology such
as “believes,” “hopes,” “may,” “anticipates,” “should,” “intends,”
“plans,” “will,” “expects,” “estimates,” “projects,” “positioned,”
“strategy” and similar expressions and are based on assumptions and
assessments made in light of management’s experience and perception of
historical trends, current conditions, expected future developments and
other factors believed to be appropriate. Forward-looking statements in
this press release are made as of the date of this press release, and
the company undertakes no duty to update or revise any such statements,
whether as a result of new information, future events or otherwise.
Forward-looking statements are not guarantees of future performance and
are subject to risks and uncertainties, many of which are outside of the
company’s control. Important factors that could cause actual results,
developments and business decisions to differ materially from
forward-looking statements are described in the sections titled “Risk
Factors” in the company’s filings with the Securities and Exchange
Commission, including its most recent Annual Report on Form 10-K and
Quarterly Reports on Form 10-Q, as well as reports on Form 8-K, and
include the following: the company’s ability to maintain or increase
sales of its products; the company’s ability to develop and
commercialize its hormone therapy drug candidates and obtain additional
financing necessary therefor; whether the company will be able to
prepare a new drug application for its TX-001HR product candidate and,
if prepared, whether the FDA will accept and approve the application;
whether the FDA will approve the company’s new drug application for its
TX-004HR product candidate and whether any such approval will occur by
the PDUFA date; the length, cost and uncertain results of the company’s
clinical trials; the potential of adverse side effects or other safety
risks that could preclude the approval of the company’s hormone therapy
drug candidates; the company’s reliance on third parties to conduct its
clinical trials, research and development and manufacturing; the
availability of reimbursement from government authorities and health
insurance companies for the company’s products; the impact of product
liability lawsuits; the influence of extensive and costly government
regulation; the volatility of the trading price of the company’s common
stock and the concentration of power in its stock ownership. PDF copies
of the company’s historical press releases and financial tables can be
viewed and downloaded at its website:


TherapeuticsMD, Inc.
DeLucia, 561-961-1900
Director, Investor Relations
Knoefler, 650-739-9952